---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-099529"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:34:49.740637+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# InMed appoints John Bathery to board; director Baldasare to depart at AGM

## Summary
- John Bathery appointed to Board effective Oct 14, 2025; Board expands to six members.
- Bathery has 30+ years pharma experience, currently Head of Global BD at Takeda, led deals exceeding $60B.
- Bryan Baldasare will not stand for re-election at 2025 AGM due to increasing professional obligations; no disagreements.
- Bathery's expertise expected to support INM-901 (Alzheimer's) and INM-089 (AMD) programs toward clinical readiness and partnerships.
- Bathery receives standard non-employee director compensation: $50,000 annual retainer, potential committee fees.

## SEC filing metadata
- accession: 0001213900-25-099529
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025099529/0001213900-25-099529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025099529/ea0261537-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-099529
- JSON: https://secwatch.observer/filing/0001213900-25-099529.json
- Plain text: https://secwatch.observer/filing/0001213900-25-099529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.